Pidilizumab Usage And Synthesis

Uses

Pidilizumab (CT-011) is a humanized IgG1k anti-PD-1 monoclonal antibody. Pidilizumab acts as a DLL1 antagonist. Pidilizumab has the potential for hematologic malignancies research[1].

References

[1] Jason R Westin, et al. Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial. Lancet Oncol. 2014 Jan;15(1):69-77. DOI:10.1016/S1470-2045(13)70551-5
[2] Aline de Oliveira Albuquerque, et al. Computationally-obtained structural insights into the molecular interactions between Pidilizumab and binding partners DLL1 and PD-1. J Biomol Struct Dyn. 2022 Sep;40(14):6450-6462. DOI:10.1080/07391102.2021.1885492

Pidilizumab(1036730-42-3)Related Product Information

• Emerfetamab
• Lymphocide
• Anrukinzumab
• Spartalizumab
• Maftivimab
• Rosmantuzumab
• Pateclizumab
• Torudokimab
• Onartuzumab
• Immunoglobulin M,anti-(human CD147 (antigen)) (mouse monoclonal ABX-CBL m-chain), disulfide with mousemonoclonal ABX-CBL light chain, pentamer